CR
Therapeutic Areas
Averoa Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Undisclosed CKD Program | Chronic Kidney Disease | Pre-clinical |
| Undisclosed Tubulopathy Program | Rare Renal Tubulopathies | Pre-clinical |
Leadership Team at Averoa
DL
Dr. Luc-André Granier
President, CEO & Medical Director
SD
Sarah Delbaere
Chief Financial Officer
MC
Mélanie Cardona
Regulatory Affairs Manager
SD
Scott Donald
Business Development Director
AG
Alexandra Guillermin
Pharmaceutical Development Manager
CT
Catherine Thompson
Clinical-Regulatory Advisor